Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells

Clinical Cancer Research

Volumn 11, Issue 21, 2005, Pages 7891-7900

  Koido, Shigeo ^a   Hara, Eiichi ^b   Homma, Sadamu ^a   Torii, Akira ^a   Toyama, Yoichi ^a   Kawahara, Hidejiro ^a   Watanabe, Michiaki ^a   Yanaga, Katsuhiko ^a   Fujise, Kiyotaka ^a   Tajiri, Hisao ^a   Gong, Jianlin ^c   Toda, Gotaro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA A24 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUCIN 1; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC RESTRICTION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELL SPECIFICITY; COLON CANCER CELL; COLORECTAL CANCER; COLORECTAL TUMOR; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE FUSION; HLA SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MULTIPLE CANCER; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FLOW CYTOMETRY; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; MONOCYTES; NEOPLASM METASTASIS; NEOPLASMS; PEPTIDES; PHENOTYPE; T-LYMPHOCYTES;

EID: 27744491292     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1330     Document Type: Article

References (35)

1. Inaba K, Witmer-Pack M, Inaba M, et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 1994;180:1849-60.
2. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
3. Sogn JA. Tumor immunology: the glass is half full. Immunity 1998;9:757-63.
4. Gilboa E. The making of a tumor rejection antigen. Immunity 1999;11:263-70.
5. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-7.
6. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
7. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-302.
8. Gong J, Chen L, Chen D, et al. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther 1997;4:1023-8.
9. Koido S, Kashiwaba M, Chen D, et al. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000;165:5713-9.
10. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996;183:317-22.
11. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
12. Russo V, Tanzarella S, Dalerba P, et al. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci U S A 2000;97:2185-90.
13. Matsuda K, Tsunoda T, Tanaka H, et al. Enhancement of cytotoxic T-lymphocyte responses patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 2004;53:609-16.
14. Mackensen A, Herbst B, Chen JL, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 2000;86:385-92.
15. Thurner B, Haendle I, Roder C, et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
16. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-61.
17. Gong J, Chen D, Kashiwaba M, et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci U S A 1998;95:6279-83.
18. Gong J, Nikrui N, Chen D, et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000;165:1705-11.
19. Koido S, Tanaka Y, Chen D, Kufe D, Gong J. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J Immunol 2002;168:2111-7.
20. Trefzer U, Weingart G, Chen Y, et al. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer 2000;85:618-26.
21. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004;2004:452-9.
22. Homma S, Kikuchi T, Ishiji N, et al. Cancer Immunotherapy by fusion of dendritic and tumor cells and rh-IL-12. Eur J Clin Invest 2005;35:279-86.
23. Chan RC, Xie H, Zhao GP, Xie Y. Dendritomas formed by fusion of mature dendritic cells with allogeneic human hepatocellular carcinoma cells activate autologous cytotoxic T lymphocytes. Immunol Lett 2002;83:101-9.
24. Trevor KT, Cover C, Ruiz YW, et al. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunol Immunother 2004;53:705-14.
25. Koido S, Ohana M, Liu C, et al. Dendritic cells fused with human cancer cells: morphology, antigen expression and T cell stimulation. Clin Immunol 2004;113:261-9.
26. Liu L, Chahroudi A, Silvestri G, et al. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med 2002;8:185-9.
27. Jerome KR, Sloan DD, Aubert M. Measuring T-cell-mediated cytotoxicity using antibody to activated caspase 3. Nat Med 2003;9:4-5.
28. Koido S, Hara E, Torii A, et al. Induction of antigen-specific CD4 and CD8 mediated T cell responses by fusions of autologous dendritic cells and metastatic colo rectal cancer cells. Int J Cancer 2005;117:587-95.
29. Michael A, Ball G, Quatan N, Wushishi F, et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005;11:4469-78.
30. + CTL in MHC class I-deficient mice through CD4 to CD8 conversion. J Immunol 2004;172:7848-58.
31. Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 2003;170:5317-25.
32. + T-cell phenotype development. Proc Natl Acad Sci U S A 1995;92:7565-9.
33. + Tcells activated in a T helper type 2-like response in vivo. Eur J Immunol 1995;25:1168-75.
34. Yang G, Hellstrom KE, Mizuno MT, Chen L. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J Immunol 1995;155:3897-903.
35. + T-cell effector function in situ. Blood 2001;98:2143-51.